Outbreak of Shiga toxin-producing Escherichia-coli-associated hemolytic uremic syndrome in Istanbul in 2015: outcome and experience with eculizumab-Reference-Cited by-同舟云学术

Outbreak of Shiga toxin-producing Escherichia-coli-associated hemolytic uremic syndrome in Istanbul in 2015: outcome and experience with eculizumab

Published:2018-08-29 Issue:12 Volume:33 Page:2371-2381
ISSN:0931-041X
Container-title:Pediatric Nephrology
language:en
Short-container-title:Pediatr Nephrol

Author:

Ağbaş Ayşe^ORCID,Göknar Nilüfer,Akıncı Nurver,Yıldırım Zeynep Yürük,Taşdemir Mehmet,Benzer Meryem,Gökçe İbrahim,Candan Cengiz,Küçük Nuran,Uzuner Selçuk,Özçelik Gül,Demirkol Demet,Sever Lale,Çalışkan Salim

Publisher

Springer Science and Business Media LLC

Subject

Nephrology,Pediatrics, Perinatology, and Child Health

Link

http://link.springer.com/article/10.1007/s00467-018-4033-0/fulltext.html

Reference32 articles.

1. Mele C, Remuzzi G, Noris M (2014) Hemolytic uremic syndrome. Semin Immunol 36:399–420

2. Hauswaldt S, Nitschke M, Sayk F, Solbach W, Knobloch JK (2013) Lessons learned from outbreaks of Shiga toxin producing Escherichia coli. Curr Infect Dis Rep 15:4–9

3. Frank C, Werber D, Cramer JP, Askar M, Faber M, an der Heiden M, Bernard H, Fruth A, Prager R, Spode A, Wadl M, Zoufaly A, Jordan S, Kemper MJ, Follin P, Muller L, King LA, Rosner B, Buchholz U, Stark K, Krause G, HUS Investigation Team (2011) Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany. N Engl J Med 365:1771–1780

4. Loirat C, Fakhouri F, Ariceta G, Besbas N, Bitzan M, Bjerre A, Coppo R, Emma F, Johnson S, Karpman D, Landau D, Langman CB, Lapeyraque AL, Licht C, Nester C, Pecoraro C, Riedl M, van de Kar NC, Van de Walle J, Vivarelli M, Fremeaux-Bacchi V, HUS International (2016) An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol 31:15–39

5. Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, Nurnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C (2013) Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 368:2169–2181

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predictors of Prolonged Mechanical Ventilation in Pediatric Patients with Hemolytic Uremic Syndrome;Journal of Pediatric Intensive Care;2024-04-30

2. Management of pediatric hemolytic uremic syndrome;The Turkish Journal of Pediatrics;2024-02-28

3. Eculizumab in Shiga toxin-producing Escherichia coli hemolytic uremic syndrome: a systematic review;Pediatric Nephrology;2023-12-06

4. Hemolytic Uremic Syndrome-Induced Acute Kidney Injury Treated via Immunomodulation with the Selective Cytopheretic Device;Blood Purification;2023

5. Antimicrobial Resistance, Pathogenic, and Molecular Characterization of Escherichia coli from Diarrheal Patients in South Korea;Pathogens;2022-03-23